Verve’s Gene Editor Cuts Cholesterol in First-in-Human HeFH Trial
BioSpace
NOVEMBER 12, 2023
When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia.
Let's personalize your content